AstraZeneca's newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal that could be worth up to $500 million. The deal gives the Anglo-Swedish ...
Will we still be speaking in an English we recognise in a thousand years' time? Alice and Neil make some educated guesses!
What’s your personality type? If you are an introvert you’re in good company; Barack Obama, JK Rowling are introverts ...
An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in a phase 3 trial, although the drugmaker thinks it has seen signs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback